下一代癌症诊断市场规模、份额和增长分析：按技术、应用、癌症类型、功能和地区 - 行业预测，2024-2031

2022年全球下一代癌症诊断市场规模将为116亿美元，预测期（2024-2031年）复合年增长率为17.8%，从2023年的136.6亿美元增长到2031年的430.2亿美元。

由于从传统实验室测试向快速就地检验的转变，下一代癌症诊断市场将显着成长。先进诊断设备、套件和试剂的商业化预计将促进这一转变。市场将受益于伴同性诊断的开拓，以增强个人化基因组医学。根据2021年全球癌症观察，2020年非何杰金氏淋巴瘤病例超过544,000例，何杰金氏淋巴瘤病例超过83,000例，白血病病例超过474,000例，多发性骨髓瘤病例数为176,000例。癌症是世界第二大死因，每年夺走约960万人的生命，因此迫切需要开发更有效的诊断工具。新的癌症生物标记和测试的持续开拓进一步推动了市场扩张，这些生物标记和测试能够实现更早、更准确的疾病检测。每年报告的新病例超过 375,000 例，死亡率超过 44%，为了应对日益增长的癌症发病率和高死亡率，研究人员正在开发一种创新的微创诊断方法。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 市场成功的关键因素
• 竞争程度
• 关键投资机会
• 市场魅力指数
• 生态系绘图
• 技术分析
• 供应链分析
• 价值链分析
• 管道分析

下一代癌症诊断市场：依技术分类

• 市场概况
• 次世代定序
• qPCR/多重检测
• 实验室晶片(LOAC)/RT-PCR
• 蛋白质微阵列
• DNA微阵列

下一代癌症诊断市场：按应用分类

• 市场概况
• 生物标誌物开发
• CTC分析
• 蛋白质体分析
• 表观遗传分析
• 遗传分析

下一代癌症诊断市场：按癌症类型划分

• 市场概况
• 肺
• 胸部
• 冒号
• 脖子
• 其他的

下一代癌症诊断市场：依功能分类

• 市场概况
• 治疗监测
• 伴同性诊断
• 预言
• 癌症筛检
• 风险分析

下一代癌症诊断市场规模：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 2023年主要企业市场定位
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率(%)，2023年

主要企业简介

• Abbott Laboratories（US）
• Agilent Technologies, Inc.（US）
• Bio-Rad Laboratories, Inc.（US）
• Danaher Corporation（US）
• Exact Sciences Corporation（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GE Healthcare（US）
• Guardant Health, Inc.（US）
• Hologic, Inc.（US）
• Illumina, Inc.（US）
• Merck & Co., Inc.（US）
• Myriad Genetics, Inc.（US）
• NanoString Technologies, Inc.（US）
• Natera, Inc.（US）
• NeoGenomics, Inc.（US）
• Qiagen NV（Netherlands）
• Quest Diagnostics Incorporated（US）
• Siemens Healthineers AG（Germany）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific, Inc.（US）
• Veracyte, Inc.（US）

Global Next Generation Cancer Diagnostics Market size was valued at USD 11.60 Billion in 2022 and is poised to grow from USD 13.66 Billion in 2023 to USD 43.02 Billion by 2031, at a CAGR of 17.8% during the forecast period (2024-2031).

The Next Generation Cancer Diagnostics Market is set for substantial growth driven by the shift from traditional laboratory testing to rapid point-of-care testing. This transition is expected to be bolstered by the commercialization of advanced diagnostic devices, kits, and reagents. The market will benefit from the development of companion diagnostics, which enhance personalized genomic medicine. According to the Global Cancer Observatory 2021, there were over 544,000 cases of non-Hodgkin lymphoma and 83,000 cases of Hodgkin lymphoma in 2020, along with 474,000 cases of leukemia and 176,000 instances of multiple myeloma. With cancer being the second leading cause of death worldwide, resulting in approximately 9.6 million deaths annually, there is an urgent need for more effective diagnostic tools. The market's expansion is further driven by the continuous development of new cancer biomarkers and tests, enabling earlier and more accurate disease detection. Researchers are focused on creating innovative, minimally invasive diagnostic methods to address the increasing incidence and high mortality rate of cancer, with over 375,000 new cases reported each year and a mortality rate exceeding 44%.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Cancer Diagnostics Market Segmental Analysis

Global Next Generation Cancer Diagnostics Market is segmented on the basis of technology, application, cancer type, function, and region. By technology, the market is segmented into next-generation sequencing, qPCR & multiplexing, lab-on-a-chip (LOAC) & RT-PCR, protein microarrays, and DNA microarrays. By application, the market is segmented into biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis. By cancer type, the market is segmented into lung, breast, colorectal, cervical, and others. By function, the market is segmented into therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Drivers of the Global Next Generation Cancer Diagnostics Market

The growing demand for personalized medicine is significantly driving the next generation cancer diagnostics market. Personalized medicine focuses on tailoring treatments based on individual genetic profiles and other unique characteristics, and advanced diagnostic tools are essential for identifying patients who will benefit most from these customized therapies. Additionally, increasing awareness about the importance of early cancer detection is further fueling market growth. Early detection improves treatment outcomes and survival rates, and next generation diagnostic tools are pivotal in facilitating early cancer detection and enhancing screening programs.

Restraints in the Global Next Generation Cancer Diagnostics Market

Reimbursement issues pose a significant restraint on the Next Generation Cancer Diagnostics Market due to the current lack of clear and standardized reimbursement policies. The slow development of these policies complicates the adoption and utilization of advanced diagnostic technologies, as both healthcare providers and patients struggle to justify the associated costs. Discrepancies in reimbursement policies across different countries, regions, and healthcare systems, coupled with ongoing policy development and a lack of consensus, further hinder the market's growth and adoption.

Market Trends of the Global Next Generation Cancer Diagnostics Market

In the Next Generation Cancer Diagnostics Market, liquid biopsy tests are gaining traction as a groundbreaking alternative to traditional tissue biopsies. These tests, which analyze blood, urine, or other bodily fluids to detect cancer cells and biomarkers, offer a less invasive and more cost-effective method for cancer diagnosis and monitoring. The enhanced frequency and accuracy of results provided by liquid biopsies have spurred increased adoption, with numerous companies actively investing in their development and integration into clinical practice.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors of The Market
• Degree Of Competition
• Top Investment Pockets
• Market Attractive Index
• Ecosystem Mapping
• Technology Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Pipeline Analysis

Global Next Generation Cancer Diagnostics Market by Technology

• Market Overview
• Next-generation Sequencing
• qPCR & Multiplexing
• Lab-on-a-chip (LOAC) & RT-PCR
• Protein Microarrays
• DNA Microarrays

Global Next Generation Cancer Diagnostics Market by Application

• Market Overview
• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis

Global Next Generation Cancer Diagnostics Market By Cancer Type

• Market Overview
• Lung
• Breast
• Colorectal
• Cervical
• Others

Global Next Generation Cancer Diagnostics Market By Function

• Market Overview
• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis

Global Next Generation Cancer Diagnostics Market Size By Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NanoString Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veracyte, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments